Organ-On-Chip Market Definition
The organ-on-chip market consists of sales of organs-on-chips by entities (organizations, sole traders and partnerships) that manufacture organs-on-chips used for drug development, toxicity testing, and personalized medicine research. Organs-on-chips (OOCs) are small plastic devices with biocompatible microfluidic chambers containing multiple live human cells in a 3D culture that simulate key physiological functions of body organs. Organs-on-chips that mimic the organ level physiology of humans are a promising alternative to animal models.
Organ-On-Chip Market Size
The market for organ-on-chip reached a value of nearly $41.6 million in 2019, having grown at 70.5% since 2015.
Growth in the historic period resulted from increased demand for personalized medicine, growing need to minimize financial losses due to late stage drug failure, substantial funding of public and private sources for OOC start-ups and research groups. Factors that negatively affected growth in the historic period were high-costs associated with OOCs, limitations of polydimethylsiloxane (PDMS), the most commonly used substrate material for the fabrication of OOCs.
Going forward, adoption of OOC technology by major pharmaceutical companies such as Roche and AstraZeneca among many others, increasing drug repurposing approaches in the OOC industry will drive growth. Factors that could hinder the growth of the OOC market in the future include compatibility problems may occur due to the lack of standardization, OOCs are not high throughput to conduct multiple assays and cell survivability issues can negatively impact the market growth.
Organ-On-Chip Market Drivers
The Key driver of the organ-on-chip market include:
Adoption Of OOC Technology By Major Pharmaceutical Companies – OOCs are now being explored worldwide as tools for developing disease models and accurately predicting drug efficacies and toxicities. Many companies and universities have been continuously looking for new and better models for drug development. The advantages of OOCs over cell culture, animal models, and human clinical trials have captured the attention of the medical and pharmaceutical communities focusing on developing targeted therapies. In May 2018, AstraZeneca partnered with Emulate, Inc. to develop OCC models to demonstrate the utility of this technology as a more predictive alternative for efficacy and safety testing of new chemical entities . In 2017, Roche collaborated with ETH Zurich and the Wyss Institute at Harvard to intensify its focus on OOC that can help in advancing human-based and personalized research and development of drugs.
Organ-On-Chip Market Restraints
The key restraint on the organ-on-chip market include:
High-Costs Associated With OOCs – OOCs are considered to be more relevant and accurate than animal models or cell cultures in drug discovery and development. However, the cost of these chips and redesigning steps to suit mass production are high. High production costs are restraining the OOC market growth as expensive redesigning process might be a burden for the relatively small companies involved. Furthermore, the conceptual designing of bioreactors, pumps for perfusion of cell culture medium, maintenance of cell environment, mechanical stimuli, and implementing cell analysis methods are all complex and require additional costs. The cost incurred in the production upscaling might also reflect on the price of the chip making it unaffordable for pharmaceutical companies. Creating an OOC is also not a simple process and the challenges that need to overcome in the process include reproducing the architectural complexity of the human tissues and organs on a device in a miniaturized fashion, and linking and arranging them in the right format for the interconnected systems to recapitulate the human tissue/organ interactions. Additionally, most companies in the pharmaceuticals industry will have to switch from polydimethylsiloxane (PDMS) prototyping and small-series to large-scale production in other materials (glass, polymer injection moulding) that will increase the expenditure and is likely to slow down the growth of OOC companies.
Organ-On-Chip Market Trends
Major trends influencing the organ-on-chip market include:
Developments In The Testing Of Human Organs-On-Chips
Human organs-on-chips (OOCs) are miniaturized versions of lungs, livers, kidneys, heart, brain, intestines and other vital human organs embedded in a chip. With advances in OOC technology, drug regulatory bodies have started testing OOCs for their reliability and their use as an alternative to animal testing. For instance, in April 2017, the US FDA announced an agreement with Emulate Inc., a USA-based biotechnology company, to evaluate the company’s human organ-on-chip technology in laboratories. The OOC technology offers a less time-consuming and cost-effective way to test drugs, foods, cosmetics and dietary supplements for efficacy and toxicity. Emulate Inc. was founded by researchers at the Wyss Institute for Biologically Inspired Engineering at Harvard University, and is the first commercial organ-on-chip venture. Companies such as Johnson & Johnson and Merck have also partnered with Emulate to test and develop applications for its human OOC technology.
Automated Monitoring Of Organs-On-Chips
OOC companies are developing research platforms for organs-on-chips that allow for continuous, real-time, automated monitoring of physiological responses to drugs. The current method of measuring the response of OOCs is manual, and is a major technical challenge, making it difficult to conduct long-term studies. The new approach involves development of biochemical sensors and physical sensors which can accurately measure different substances released by OOCs, temperature, oxygen levels and pH values. This also helps integrate multiple existing organ-on-chip systems. The new integrated multisensory platform enhances the performance of organ-on-chip models for drug screening and personalized medicine. For instance, a research team from Brigham and Women’s Hospital in the USA has developed a novel technology platform that enables continuous and automated monitoring of OOCs.
Opportunities And Recommendations In The Organ-On-Chip Market
Opportunities –The top opportunities in the global OOC market will arise in the multi-organs-on-chip segment, which will gain $15.1 million, toxicology research segment by application will gain $22.3 million, biopharmaceutical companies segment by end-users will gain $41.7 million of global annual sales by 2023 and the OOC market will gain $40.6 million in North America
Recommendations –To take advantage of the opportunities, The Business Research Company recommends the OOC companies to consider develop human-on-chip models, focus on R&D to develop disease models, focus on pricing based on economies, use Direct-To-Consumer (DTC) advertising and collaborate with pharmaceutical companies.
Organ-On-Chip Market Segmentation
The organ-on-chip market is segmented by organ type, by application, by end users, and by geography.
By Organ Type -
The organ-on-chip market can be segmented by product type into
Liver-on-chip had the highest growth rate of nearly 76.2% during the historic period.
- a) Lung-On-Chip
- b) Multi-Organs On Chip
- c) Heart-On-Chip
- d) Liver-On-Chip
- e) Intestine-On-Chip
- f) Kidney-On-Chip
- g) Skin-On-Chip
- h) Blood-Brain-Barrier-On-Chip
- i) Other Organ Models
The organ-on-chip market can be segmented by application into
Drug discovery had the highest growth rate of nearly 72.1% during the historic period.
- a) Toxicology Research
- b) Drug Discovery
- c) Molecular Biology
- d) Disease Modelling
- e) Food Safety
- f) Other Applications
By End Users
The organ-on-chip market can be segmented by end users into
Academics had the highest growth rate of nearly 71.5% during the historic period.
- a) Biopharmaceutical companies
- b) Academics
- c) Food & Beverages
- d) Other commercial industries
By Products And Services
The organ-on-chip market can be segmented by products and services
Devices had the highest growth rate of nearly 70.6% during the historic period.
- a) Devices
- b) Testing Services
By Type Of Material
The organ-on-chip market can be segmented by type of material
Polymer had the highest growth rate of nearly 207.8% during the historic period.
- a) Polymer
- b) PDMS
- c) Glass
- d) Silicon
By Geography- The organ-on-chip market is segmented into
North America is the largest market for organ-on-chip, accounting for 56.6% of the global market. It was followed by Europe, Asia, and rest of the world. Going forward, Europe and Asia will be the fastest growing regions in the organ and chips market.
- o North America
- o Europe
- o Asia
- o Rest of the World
Organ-On-Chip Competitive Landscape
Major Competitors are:
Other Competitors Include:
- • Emulate Inc.
- • AxoSim Inc.
- • Kirkstall
- • TissUse GmbH
- • Nortis Inc.
- • Mimetas BV
- • Biochip
- • Hurel Corporation
- • Micronit
- • Tara Biosystems
- • BiomimX SRL
- • Elveflow
- • SynVivo
- • BeonChip
- • Mesobiotech
- • Cherry Biotech
- • 4DCell
- • uFluidix Inc.
- • CN Biosystems
- • Hurel Corporation
- • InSphero AG,
- • Nortis Inc.
- • HemoShear
- • Ascendance Bio
- • Organovo Holdings, Inc.
- • Others